Currently, there are 38.26M common shares owned by the public and among those 28.57M shares have been available to trade.
The company’s stock has a 5-day price change of -73.58% and -80.24% over the past three months. LPTX shares are trading -77.39% year to date (YTD), with the 12-month market performance down to -74.41% lower. It has a 12-month low price of $1.68 and touched a high of $4.79 over the same period. LPTX has an average intraday trading volume of 422.06K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -76.44%, -77.17%, and -75.78% respectively.
Institutional ownership of Leap Therapeutics Inc (NASDAQ: LPTX) shares accounts for 31.99% of the company’s 38.26M shares outstanding.
It has a market capitalization of $24.91M and a beta (3y monthly) value of 0.21. The earnings-per-share (ttm) stands at -$1.93. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.99% over the week and 11.89% over the month.
Earnings per share for the fiscal year are expected to increase by 53.39%, and 31.00% over the next financial year.
Looking at the support for the LPTX, a number of firms have released research notes about the stock. Rodman & Renshaw stated their Buy rating for the stock in a research note on June 28, 2024, with the firm’s price target at $8. Mizuho coverage for the Leap Therapeutics Inc (LPTX) stock in a research note released on October 04, 2021 offered a Buy rating with a price target of $6. Robert W. Baird was of a view on June 04, 2021 that the stock is Outperform, while Piper Sandler gave the stock Overweight rating on June 29, 2020, issuing a price target of $6. Robert W. Baird on their part issued Outperform rating on February 11, 2020.
